News | Radiation Dose Management | May 12, 2017

Study Reveals Low Adoption of IAEA Recommendations for Reduced Nuclear Cardiology Radiation Exposure

Majority of sites worldwide found to be using less than half of the suggested quality metrics to achieve dose of 9 mSv or less

Study Reveals Low Adoption of IAEA Recommendations for Reduced Nuclear Cardiology Radiation Exposure

May 12, 2017 — A study in 65 countries has revealed low adoption of International Atomic Energy Agency (IAEA) recommendations to reduce nuclear cardiology radiation exposure. The research was presented at ICNC 2017, May 7-9 in Vienna Austria, by Edward Hulten, M.D., a cardiologist at the Walter Reed National Military Medical Center, Bethesda, Md.

Nuclear cardiology uses small amounts of radioactive tracers that are injected into the veins and taken up by the heart. A gamma camera images the radiation from the tracer. The cardiac images are used to measure the heart size and function, identify coronary heart disease and predict the risk of a heart attack.

Hulten said, “Nuclear cardiology is a key part of contemporary cardiology management and around 15 to 20 million procedures are performed annually. It gives information regarding diagnosis, prognosis, and the effects of therapeutic interventions.”

“Concerns have been raised about tests, including nuclear cardiology, that expose patients to ionizing medical radiation,” he continued. “Medical radiation potentially raises the lifetime risk of cancer which is important for all patients, especially younger patients or when considering additional radiation over time from further medical studies.”

A goal of 9 mSv or less radiation exposure per scan was recommended by the American Society of Nuclear Cardiology (ASNC) in 2010. It was noted in a 2016 International Atomic Energy Agency (IAEA) nuclear cardiology guideline but not formally endorsed as a recommendation.

The IAEA developed eight quality metrics for responsible radiation use in nuclear cardiology:

  • Avoiding thallium 201 stress testing;
  • Avoiding dual isotope testing;
  • Avoiding too much technetium-99m and thallium 201;
  • Using stress-only imaging;
  • Use of camera technologies to reduce dose;
  • Use of weight-based dosing strategies for technetium-99m; and
  • Avoiding inappropriate dosing that can lead to “shine-through” artifacts.

The IAEA Nuclear Cardiology Protocols Study (INCAPS) assessed adherence to the eight quality metrics. The present analysis investigated which metrics were most helpful in meeting the ASNC’s 9 mSv target. During one week in 2013, 308 nuclear cardiology laboratories were studied in 65 countries in Africa, Asia, Europe, Latin America, North America and Oceania.

The survey included 7,911 nuclear cardiology scans. There was significant variability in adherence to the quality metrics across laboratories and regions. There was low adherence overall, with the majority of sites implementing less than half of the quality metrics.

When the researchers performed multivariable logistic regression analysis, they found that the practices most strongly associated with achieving a 9 mSv or less scan were the use of stress or rest only imaging, avoiding thallium, and use of camera technologies to reduce radiation dose.

Hulten said, “When the 9 mSv recommendation was made in 2010 it was suggested that it should be achieved in 50 percent of scans by 2014. The INCAPS survey shows that there is still work to do. It is possible to reduce radiation exposure with existing techniques. Cadmium zinc telluride (CZT) cameras are more sensitive and allow for reduced dose scanning. With certain tracers you can achieve 1 mSv or less. But some scans use more than 30 mSv, so there is huge variability.”

Not every site has all of the hardware and technology, said Hulten, so the first step is to look at what is possible within each lab. He said, “There are improvements every lab can make regardless of money – for example multiple position imaging, weight-based dosing and stress-only techniques. They do require adapting existing workflows which takes leadership but they should be feasible in most labs.”

He added, “Eventually cameras wear out and perhaps the decision on a replacement could factor in a reduced radiation dose which also lowers false positive tests and has the potential to reduce lab costs.”

Hulten concluded, “The INCAPS survey is a crucial step towards improving patient care in the field of nuclear cardiology by quantifying worldwide adherence to best practices. Any test involving ionising radiation will increase cancers within a population but the risk must be weighed against the benefit of gaining information about heart disease. The 9 mSv goal is achievable, and the lower the better.”

For more information: www.escardio.org

Related Content

NCCN Guidelines for Chest CT in Breast Cancer Reduce False Positives, Healthcare Spending
News | Breast Imaging | June 26, 2017
June 26, 2017 — A recent study appears to confirm the recommendations of the National Comprehensive Cancer Network (N
MRI Plus Mammography Improves Detection of New Breast Cancer After Surgery
News | Breast Imaging | June 22, 2017
A new article published by JAMA Oncology compares outcomes for combined mammography and magnetic resonance imaging (MRI...
RadNet Inc. Acquires Equity Stake in Medic Vision
News | Radiation Dose Management | June 21, 2017
June 21, 2017 — RadNet Inc. and Medic Vision Imaging Solutions Ltd.
Diagnostic Radiation Exposure Safe for Children, Experts State
News | Pediatric Imaging | June 21, 2017
In an article published in the June 2017 issue of The Journal of Nuclear Medicine, researchers assert that exposure to...
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
New Image Wisely Radiation Safety Case Discusses Child-Sizing CT Dose
News | Radiation Dose Management | June 19, 2017
The tenth special edition Image Wisely Radiation Safety Case is now available to help radiologists, imaging...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
Overlay Init